CONTRACEPTION: FROM ANTIQUITY TO THE PRESENT DAY


Cite item

Full Text

Abstract

The article highlights the main historical facts related to the development of contraception from antiquity to the present day. Particular attention is paid to the various options for hormonal contraception, including combined oral medications, intrauterine contraceptives, vaginal and cutaneous hormone-releasing systems. Potentials for therapeutic and preventive use of hormonal contraceptives are discussed. It is emphasized that contraception has no adverse effects on fertility and is effective in maintenance of reproductive health

References

  1. Нестеровская И.В., Осипова А.А., Эволюция контрацептивных вагинальных рилизинг-систем // Проблемы репродукции 2007. № 4. C. 59-63.
  2. Прилепская В.Н., Межевитинова Е.А. Гормональная контрацепция.М., 2011. C. 156-58.
  3. Ромащенко О.В. История развития женской сексологии // Медицинские аспекты здоровья женщины 2007. № 3. C. 14-16.
  4. Archer DF, Jensen JT, Johnson JV, et al. Evaluation of a continuous regimen of levonorgestrel/ethinylestradiol: phase 3 study results. Contraception 2006;74:439-45.
  5. Benagiano G, Bastianelli C, Farris M. Contraception today. Ann NY Acad Sci 2006;1092:1-32.
  6. Benagiano G, Carrara S, Filippi V. Safety, efficacy and patient satisfaction with continuous daily administration of levonorgestrel/ethinylestradiol oral contraceptives. Pat Pref Adher 2009;3:131-43.
  7. Cagnacci A, Ferrari S. Evolution and future of contraception. Minerva Ginecol 2010;62(4):303-17.
  8. Calaf I, Alsina J. After 50 years of ethinylestradiol, another oestrogen in combined oral contraceptives. Eur J Contracept Reprod Health Care 2010;15:1-3.
  9. Dhont M. History of oral contraception. Eur J Contracept Reprod Health Care 2010;15(2):12-8.
  10. Diczfalusy E. Gregory Pincus and steroidal contraception. Acta Obstet Scand Suppl 1982;105:7-15.
  11. Dore DD, Norman H, Loughlin J, et al. Extended case-control study results on thromboembolic outcomes among transdermal contraceptive users. Contraception 2010;81(5):408-13.
  12. Gupta SK, Gupta N, Suman P, et al. Zona pellucida-based contraceptive vaccines for human and animal utility. J Reprod Immunol 2011;88(2):240-46.
  13. Hannaford PC, Iversen L, Macfarlane TV, et al. Mortality among contraceptive pill users: Cohort evidence from RoyalCollege of General Practitioners'OralContraception Study. BMJ 2010;340:c927. doi: 10.1136/bmj.c927.
  14. He YP, Xu WX, Hong AZ, et al. Immunogenic comparison for two different recombinant chimeric peptides (CP12 and CP22) containing one or two copies of three linear B cell epitopes from β-hCG subunit. J Biotechnol 2011;151(1):15-21.
  15. Kiley J, Hammond C. Combined oral contraceptives: A comprehensive review. Clin Obstet Gynecol 2007;50:868-77.
  16. Lete I, et al. Economic evaluation of the levonorgestrel-releasing intrauterine system for the treatment of dysfunctional uterine bleeding in Spain. Eur J Obstet Gynecol Reprod Biol 2011;154(1):71-80.
  17. Lidegaard O, Lokkegaard E, Svendsen AL, et al. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009;339:b2890. doi: 10.1136/bmj.b2890.
  18. Nelson HD. Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. JAMA2004;291(13):1610-20.
  19. Reid RL, Westhoff C, Mansour D, et al. Oral contraceptives and venous thromboembolism. Consensus opinion from an international workshop held in Berlin, Germany in December 2009. J Fam Plann Reprod Health Care2010;36:117-22.
  20. Risk of thromboembolic disease in women taking oral contraceptives. A preliminary communication to the Medical Research Council by a Subcommittee. Br Med J 1967;2:355-9.
  21. Sitruk-Ware R. New progestagens for contraceptive use. Hum Reprod Update 2006;12:169-78.
  22. Speroff L, Fritz MA. Clinical Gynecologic Endocrinology and Infertility. 7th edn. Philadelphia, PA, USA: Lippincott Williams& Wilkins 2005:559.
  23. Speroff L. A good man -Gregory Goodwin Pincus. Portland, Oregon: Arnica Publishing, Inc. 2009.
  24. Tariq N, et al. Efficacy of levonorgestrel intrauterine system (LNG-IUS) for abnormal uterine bleeding and contraception, J Coll Physicians Surg Pak 2011;21(4):210-13.
  25. WHO. Venous thromboembolic disease and combined oral contraceptives: Results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995;346:1575-82.
  26. Wiegratz I, Kuhl H. Metabolic and clinical effects of progestogens. Eur J Contracept Reprod Health Care 2006;11:153-61.
  27. Zakharova MY, et al., Risk Factors for Heart Attack, Stroke, and Venous Thrombosis Associated With Hormonal Contraceptive Use. Clin Appl Thromb Hemost 2010;7. Epub ahead of print.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies